Nkarta Stock

Nkarta PEG

The PEG Ratio (Price/Earnings-to-Growth) of Nkarta (NKTX) as of Aug 10, 2026 is -0.38. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was -0.04 — a change of 830.43% (lower).

PEG

-0.38

YoY

830.43%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Nkarta is 2026 -0.38 . PEG Ratio (Price/Earnings-to-Growth) of Nkarta was 2025 -0.04 . It decreases by 830.43% lower compared to the previous year.
Access this data via the Eulerpool API

Nkarta Stock analysis

What does Nkarta do? Nkarta Inc is a biopharmaceutical company based in South San Francisco, California. The company was founded in 2015 by Dr. Raphael Rousseau (CEO) to develop a groundbreaking new therapy for cancer patients. The business model of Nkarta is based on the development of novel CAR-T cell therapies. These are a special type of immunotherapy in which the patient's own immune cells are genetically modified and used to target tumor cells. Unlike conventional chemotherapy or radiation, which can also attack healthy cells, CAR-T cell therapies specifically target cancer cells while sparing the surrounding healthy tissue. Nkarta is divided into various business areas, including research and development of new therapies, manufacturing and production of CAR-T cells, and clinical trials and approval processes for broad application. One of Nkarta's key products is NKR-2, a CAR-T cell therapy based on natural killer cells. These cells have high activity against cancer cells and can respond quickly to threats. NKR-2 differentiates itself from other therapies by its ability to be effective even at low concentrations. This means that fewer cells are needed and the risk of unwanted side effects is reduced. Nkarta is also working on other projects, including NKX101, which specializes in treating solid tumors, and Voretigene Neparvovec, a gene therapy for the rare hereditary retinal disease. In 2020, Nkarta entered into a partnership with CRISPR Therapeutics to explore the joint potential of CRISPR gene editing and CAR-T cell therapy. The collaboration aims to improve the precision and effectiveness of CAR-T cell therapies and ultimately increase the chances of a cure for cancer patients. Overall, Nkarta has had an impressive success story in recent years. The company has raised several million dollars in funding and continues to expand. The groundbreaking technology of CAR-T cell therapies is promising and has the potential to have a sustainable impact on healthcare. With Nkarta at the forefront, the future could look much more hopeful for cancer patients. Nkarta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nkarta stock

PEG Ratio (Price/Earnings-to-Growth) of Nkarta is -0.38 in 2026.

PEG Ratio (Price/Earnings-to-Growth) of Nkarta changed from -0.04 to -0.38, representing a 830.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Nkarta since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Nkarta with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Nkarta

All Key Metrics — Nkarta